MedTrace Logo

Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line

NCT05734053 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2023-08-21

No results posted yet for this study

Summary

This was a non-interventional observational study within the routine chronic myeloid leukemia treatment practice; no further tests were required apart from the assessments routinely performed for Chronic myeloid leukemia patients treated with nilotinib.

Conditions

  • Chronic Myeloid Leukemia

Interventions

OTHER

Nilotinib

There was no treatment allocation. Patients administered Nilotinib by prescription could be enrolled.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-28
Primary Completion
2022-09-08
Completion
2022-09-08

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05734053 on ClinicalTrials.gov